We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Inovio Pharmaceuticals (INO - Free Report) . Shares have added about 10.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Inovio due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Inovio Misses on Q4 Earnings & Revenues
Inovio incurred a loss of 34 cents per share for the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 24 cents.
Inovio generated revenues of $2.5 million in fourth-quarter 2018, missing the Zacks Consensus Estimate of $2.69 million. Revenues decreased 71.6% from the year-ago quarter’s figure of $8.8 million due to significantly lower collaboration payments and grants compared to the year-ago period.
Research and development expenses increased 7.3% to $26.4 million due to higher expenses related to clinical studies, partially offset by lower expenses related to the DARPA Ebola grant.
General and administrative expenses decreased 30% to $5.6 million in the fourth quarter.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 35.45% due to these changes.
VGM Scores
Currently, Inovio has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Inovio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Inovio Pharmaceuticals (INO - Free Report) . Shares have added about 10.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Inovio due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Inovio Misses on Q4 Earnings & Revenues
Inovio incurred a loss of 34 cents per share for the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 24 cents.
Inovio generated revenues of $2.5 million in fourth-quarter 2018, missing the Zacks Consensus Estimate of $2.69 million. Revenues decreased 71.6% from the year-ago quarter’s figure of $8.8 million due to significantly lower collaboration payments and grants compared to the year-ago period.
Research and development expenses increased 7.3% to $26.4 million due to higher expenses related to clinical studies, partially offset by lower expenses related to the DARPA Ebola grant.
General and administrative expenses decreased 30% to $5.6 million in the fourth quarter.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 35.45% due to these changes.
VGM Scores
Currently, Inovio has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Inovio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.